Search - tctmd.com

Displaying 21 - 40 of 44

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

Caitlin E. Cox

January 31, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

L.A. McKeown

December 07, 2018

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

Todd Neale

September 22, 2018

News Daily News

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

L.A. McKeown

May 08, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

L.A. McKeown

September 13, 2017

News Conference News ISET 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

Caitlin E. Cox

February 17, 2017

News Conference News ISET 2017

Underappreciated by Clinicians, Critical Limb Ischemia Has Dire Fallout for Patients

Caitlin E. Cox

February 07, 2017

News Conference News VIVA 2016

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

L.A. McKeown

September 21, 2016

News Daily News

Drug-Coated Balloons Beat Angioplasty for SFA In-Stent Restenosis, but Long-Term Solutions Needed

Caitlin E. Cox

July 07, 2016

News Industry News

CARDIONOVUM Announces Enrollment Completion of RAPID Trial

June 06, 2016

News Industry News

CARDIONOVUM Announces Enrollment of First Patient in MAGNIFICENT Trial

April 07, 2016

News Conference News ISET 2016

Drug-Coated Balloon Angioplasty Superior for In-Stent Restenosis of SFA, but Results Leave Much To Be Desired

Michael O'Riordan

February 10, 2016

Presentation ISET 2016

Drug-Coated Balloons in the SFA: A Class of Devices with Differentiated Outcomes?

Presenter: Thomas Zeller

February 07, 2016

News Industry News

Drug-Coated Balloon Shown To Be Superior To Conventional Angioplasty In Treating Superficial Femoral Artery Disease After Two Years

October 14, 2015

News Conference News EuroPCR 2015

Studies Provide Encouraging Results for DCB in Long SFA Lesions

Caitlin E. Cox

May 22, 2015

News Daily News

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

April 14, 2014

News Daily News

First-Generation Bioresorbable Stent Performs Well in SFA Lesions

Jason Kahn

February 20, 2014

Advertisement

TCTMD’s Top 10 Most Popular Stories for January 2019

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

Underappreciated by Clinicians, Critical Limb Ischemia Has Dire Fallout for Patients

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

Drug-Coated Balloons Beat Angioplasty for SFA In-Stent Restenosis, but Long-Term Solutions Needed

CARDIONOVUM Announces Enrollment Completion of RAPID Trial

CARDIONOVUM Announces Enrollment of First Patient in MAGNIFICENT Trial

Drug-Coated Balloon Angioplasty Superior for In-Stent Restenosis of SFA, but Results Leave Much To Be Desired

Drug-Coated Balloons in the SFA: A Class of Devices with Differentiated Outcomes?

Drug-Coated Balloon Shown To Be Superior To Conventional Angioplasty In Treating Superficial Femoral Artery Disease After Two Years

Studies Provide Encouraging Results for DCB in Long SFA Lesions

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

First-Generation Bioresorbable Stent Performs Well in SFA Lesions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content